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ABSTRACT
Glutathione S-transferase isoenzymes (GSTs) catalyze the conjugation reaction between glutathione and electrophilic 
compounds. GSTs are involved in the detoxification of toxic and carcinogenic compounds, thus protecting the body from 
toxic injuries. Tocotrienols are part of the vitamin E family and is believed to possess potent antioxidant activity. The 
objective of this study was to determine the effect of increasing doses of tocotrienol rich fraction (TRF) supplementation 
on liver GSTs gene and protein expression. A total of 30 male ICR white mice were divided into five groups (n=6 for each 
group) and given treatment for 14 days through oral supplementation. Groups were divided as follows: - three groups 
administered with TRF at doses of 200, 500 and 1000  mg/kg, respectively, a positive control group administered with 100 
mg/kg butylated hydroxyanisole (BHA) and a control group administered with only the vehicle (corn oil). At day 15, the 
mice were sacrificed and their livers isolated. Total RNA was extracted from the liver and quantitative real-time polymerase 
chain reaction (qPCR) assays were performed to analyze GSTs gene expression. Total liver protein was also extracted 
and the protein expression of GSTs was determined by Western blotting. The results showed that TRF oral supplementation 
caused a significant dose-dependent increase in liver GST isoenzymes gene and protein expression, compared to controls. 
In conclusion, TRF oral supplementation for 14 days resulted in increased gene and protein expression of GST isoenzymes 
in mice liver dose-dependently, with the highest expression seen in mice treated with 1000 mg/kg TRF.
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ABSTRAK
Glutation S-transferase (GST) isoenzim merupakan enzim yang memangkinkan tindak balas konjugasi antara glutation 
dan sebatian hidrofilik. GST terlibat dalam detoksifikasi sebatian toksik dan karsinogenik dan oleh itu melindungi badan 
daripada kecederaan toksik. Tokotrienol adalah sebahagian daripada keluarga besar vitamin E dan dipercayai mempunyai 
aktiviti antioksidan yang poten. Objektif kajian ini adalah untuk menentukan kesan pemberian dos secara meningkat 
fraksi kaya tokotrienol (TRF) terhadap pengekspresan gen dan protein beberapa isoenzim GST di hepar. Sebanyak 30 ekor 
mencit putih jantan ICR dibahagikan kepada lima kumpulan (n=6 untuk setiap kumpulan) dan dirawat secara suplementasi 
oral selama 14 hari. Kumpulan dibahagikan seperti berikut: - tiga kumpulan dirawat dengan pelbagai dos TRF (200, 
500 dan 1000 mg/kg), kumpulan kawalan positif yang dirawat dengan 100 mg/kg butilated hidroksianisol (BHA) dan 
kumpulan kawalan yang hanya diberi bahan pelarut (minyak jagung). Pada hari ke-15, tikus telah dibunuh dan heparnya 
diasingkan. RNA jumlah diekstrak daripada hepar dan seterusnya asai reaksi rerantai polimerase kuantitatif (qPCR) telah 
dilakukan untuk menganalisis pengekspresan gen beberapa isoenzim GST. Protein jumlah hepar juga telah diekstrak 
dan pengekspresan protein beberapa isoenzim GST ditentukan dengan menggunakan kaedah ‘Western blot’. Keputusan 
kajian menunjukkan bahawa suplementasi oral TRF menyebabkan peningkatan signifikan pengekspresan gen dan protein 
beberapa isoenzim GST yang bersandarkan dos, berbanding kumpulan kawalan. Kesimpulannya, suplementasi oral TRF 
selama 14 hari pada mencit berupaya menyebabkan peningkatan pengekspresan gen dan protein beberapa isoenzim GST 
yang bersandarkan dos dengan pengekspresan tertinggi diperhatikan pada mencit yang dirawat dengan 1000 mg/kg TRF.
Kata kunci: Glutation S-transferase; hepar; isoenzim; tokotrienol; TRF
INTRODUCTION
Eight different isoenzymes of vitamin E exist naturally - 
α, β, γ, δ tocopherols and α, β, γ, δ tocotrienols (Sylvester 
& Theriault 2003). The chromanol ring structure is present 
in both tocopherols and tocotrienols, which is responsible 
for their potent antioxidant activities. Tocotrienols 
differ from tocopherols in terms of the structure of 
their side chains (Das 2011). The phytyl side chains 
of the chromanol rings of tocotrienols are unsaturated, 
whereas the side chains of the chromanol rings of 
tocopherols are saturated (Sambanthamurthi et al. 2000). 
Another important difference lies in the observation that 
tocotrienols have greater antioxidant power compared 
to tocopherols (Inokuchi et al. 2003; Pruthi et al. 2001). 
Tocopherols are largely found in corn, olive, soybean, 
sesame, peanut and sunflower oils. Tocotrienols can be 
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found at lesser quantities in certain grains as barley, rice 
and wheat. Interestingly, the most widely available natural 
source that contains huge amounts of tocotrienols is palm 
oil (Atia & Abdullah 2013; Sen et al. 2010). The vitamin 
E found in palm oil is made up of 70% tocotrienols 
and 30% tocopherols (Sen et al. 2010; Sundram et al. 
2003). A standardized tocotrienol-rich fraction (TRF) 
derived from palm oil consists mainly of α, β, γ and 
δ-tocotrienols. TRF is obtained from palm oil after it 
has undergone esterification, distillation, crystallization 
and chromatography (Sundram & Gapor 1992). TRF 
is the most common and cost-effective preparation of 
tocotrienols.
 It has been well established that vitamin E possess 
strong antioxidant activity. It is also the most important 
lipid soluble antioxidant in humans (Nesaretnam et al. 
1995). This is due to the presence of a phenolic group 
in the chromanol ring which neutralizes free radicals 
by converting them into more stable products. The 
potential beneficial effects of TRF towards health had been 
widely implicated through various animal studies. For 
example, a previous study had suggested that tocotrienols 
were significantly more efficient than tocopherols 
against lipid peroxidation and protein oxidation in rat 
brain mitochondria and liver microsomes (Budin et 
al. 2009). A recent study performed in rats indicated 
that TRF supplementation was able to protect the liver 
from oxidative damage due to subchronic fenitrothion 
treatment (Jayusman et al. 2017). The results of another 
recent study showed that long term TRF supplementation 
significantly increased the antioxidant enzymes activities 
in skeletal and heart muscles in aging mice (Karim 
et al. 2015). However, only a few studies have been 
conducted in order to observe the health benefit effects 
of TRF administration to humans. One such study in 
humans showed that TRF supplementation to individuals 
over 50 years of age resulted in improvement of plasma 
cholesterol levels, advanced glycosylation end products 
(AGEs) levels and antioxidant enzymes activities as 
well as reduction in protein damage, all of which might 
indicate a restoration of redox balance in these elderly 
individuals (Chin et al. 2011).
 A previous research had tried to link the antioxidant 
activities of vitamin E with the induction of several 
phase II xenobiotic metabolizing enzymes involved 
in cancer chemoprevention (Mustacich et al. 2009). 
Most phase II xenobiotic metabolizing enzymes such 
as the glutathione S-transferase isoenzymes (GSTs) 
had been shown to be mainly regulated by nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) (Abdullah et 
al. 2012; Kitteringham et al. 2010) and are important 
for cellular defense by hastening the removal of free 
radicals and toxic by-products. As such, the GSTs are 
therefore postulated to play a protective role against 
cancer and other diseases (Aleksunes & Manautou 2007). 
GSTs are phase II detoxification enzymes that catalyze 
the conjugation of several endogenous and exogenous 
electrophilic compounds. In mammals, GSTs are divided 
into numerous cytosolic, mitochondrial and microsomal 
GST isoenzymes. The cytosolic isoenzymes are encoded 
by five related gene families (known as alpha (α), mu (μ), 
pi (π), sigma (σ) and theta (θ) GST), while the membrane-
bound isoenzymes and microsomal GSTs are encoded by 
single genes and both have originated separately from 
the soluble GSTs (Hayes et al. 2005). GST upregulation 
is essential for the redox state of the cell because GST 
catalyzes the conjugation of the reduced glutathione, 
which is a major intracellular antioxidant (Cheng et al. 
2011). Previous studies had indicated that tocotrienol 
administration in rats was able to modulate the activity 
of GST in rat liver (Iqbal et al. 2004; Rahmat et al. 1993). 
However, in these studies, only the GST enzyme activity 
was measured and no attempt was made to measure the 
gene and protein expression of different GST isoenzymes 
in rat liver after tocotrienol treatment. Furthermore, no 
study has been done in mice to investigate the effect of 
tocotrienol administration on the various GST isoenzymes 
in mice liver. Therefore, the objective of this study was 
to investigate the ability of three different doses of TRF to 
modulate GSTs at the gene and protein levels in the liver 
of ICR male white mice.
 Studies performed on animal models suggested 
that GSTs are implicated in the prevention of chemically 
induced hepatotoxicity (Ajith et al. 2007; Gum et al. 
2007). Increased expression of GSTs is suggested to 
confer increased resistance towards hepatotoxicity, 
while decreased GSTs expression is thought to increase 
the risk of hepatotoxicity (Morishita et al. 2006; 
Tanaka et al. 2007). In humans, the clinical importance 
of diminished endogenous GSTs expression and 
activity had been recognized for quite some time. It 
was discovered that individuals with homozygous 
glutathione S-transferase mu 1 (GSTM1) gene deletions, 
which resulted in decreased GSTM1 activity, appeared 
to be more susceptible to DNA damage and are more 
at risk of developing lung adenocarcinoma (Cantlay 
et al. 1994). It had also been suggested that decreased 
activity of glutathione S-transferase mu 1 (GSTM1) and 
glutathione S-transferase theta 1 (GSTT1) isoenzymes 
was associated with environmentally related cancers and 
alcoholic liver disease (Ladero et al. 2005; Martinez et 
al. 2006; Parl 2005). Human subjects with the double‐
null GSTM1 and GSTT1 genotype were found to be 
more susceptible to develop drug-induced liver injury 
(Lucena et al. 2008). The presence of abnormal variants 
of glutathione S-transferase pi 1 (GSTP1) genotypes was 
linked to decreased GSTP1 enzyme activity in certain 
individuals, which resulted in ineffective detoxification 
of carcinogens compared to individuals with wild-type 
GSTP1 genotype (Sundberg et al. 1998; Zimniak et al. 
1994). Therefore, it would be interesting to find out 
whether dietary supplementation with TRF could increase 
liver GSTs expression dose-dependently, which could 
theoretically leads to reduced risk of experiencing drug/
chemical-induced hepatotoxicity.
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MATERIALS AND METHODS
MATERIALS
TRF (Gold Tri.E70) was purchased from Sime Darby 
Bioorganic (Kuala Lumpur, Malaysia) and contains 
α-tocopherol at 159.5 mg/g, α-tocotrienol at 205.1 mg/g, 
β-tocotrienol at 32.9 mg/g, γ-tocotrienol at 249.8 mg/g and 
δ-tocotrienol at 119 mg/g. TRIzol reagent was purchased 
from Life Technologies (Carlsbad, California, USA). iScript 
cDNA synthesis kit, iQ SYBR Green supermix (2X) kit and 
48-well MJ Mini thermal cycler were purchased from Bio-
Rad (Hercules, California, USA). Real-time PCR primers 
were purchased from Vivantis technologies (Oceanside, 
CA, USA). RIPA lysis buffer and goat anti-rabbit IgG 
peroxidase secondary antibody were purchased from Santa 
Cruz Biotechnology (USA). Chemiluminescence Western 
blotting detection reagents were purchased from Amersham 
(Uppsala, Sweden). Nitrocellulose membrane and Ponceau 
S solution were purchased from Sigma-Aldrich (Seelze, 
Germany). GSTA1 polyclonal primary antibody, GSTM 
polyclonal primary antibody, GSTP polyclonal primary 
antibody and β-actin rabbit polyclonal antibody were 
purchased from Abcam Biotechnology (Cambridge, UK). 
All other chemicals were purchased from Sigma-Aldrich 
unless otherwise stated.
ANIMAL HANDLING AND EXPERIMENTAL DESIGN
Male ICR white mice (25-30 g) were used in this study and 
were obtained from the Universiti Kebangsaan Malaysia 
Laboratory Animal Research Unit (LARU). The mice were 
kept in clean polypropylene cages in a ventilated room, 
with food and water available ad libitum. Food intake and 
body weight of mice were measured daily. Animals were 
treated with three different doses of TRF (dissolved in corn 
oil). The mice were divided into 5 groups. Mice in the first 
group (n = 6) was designated as the control group and were 
given only the vehicle, i.e. corn oil. Mice in the second 
group (n = 6) were treated with 200 mg/kg TRF followed by 
the third group (n = 6) treated with 500 mg/kg TRF and the 
fourth group (n = 6) treated with 1000 mg/kg TRF. Mice in 
the fifth group (n = 6), i.e. the positive control group, were 
treated with 100 mg/kg butylated hydroxyanisole (BHA). 
The doses of TRF chosen, as well as the time point and 
duration of TRF treatment, were based on previous studies 
done by Ima-Nirwana et al. (2011) and Oo et al. (1992). 
The justification for the use of BHA as the positive control 
and the dose of BHA chosen was based on a previous study 
done by Jaeschke and Wendel (1986). All treatments were 
administered via oral gavage for 14 consecutive days. 
At day 15, mice were sacrificed via cervical dislocation. 
Their livers were subsequently isolated, snapped frozen in 
liquid nitrogen and stored at -80°C until further use. All 
experimental procedures involving animals were approved 
by the Universiti Kebangsaan Malaysia Animal Ethics 
Committee (UKMAEC) with the approval number: PP/
FAR/2011/AZMAN/22-MARCH/361-MAY2011-MAY-2013.
RNA EXTRACTION
Total RNA from frozen liver tissues was isolated 
using TRIzol reagent, according to the manufacturer’s 
instructions. Isopropyl alcohol (Sigma, USA) was added 
during each extraction step to precipitate the total RNA. 
The extracted total RNA pellet was then washed with 75% 
ethanol and dried before being dissolved in RNase-free 
water. Total RNA was stored at -80°C immediately after 
extraction. Concentration and purity of the extracted RNA 
were determined by NanoDrop spectrophotometer 2000c 
(Thermo Scientific, USA) at a wavelength of 260 nm 
(OD260). RNA with RNA integrity number (RIN) ranging 
from 7 to 10 and absorbance ratio of A260 to A280 ranging 
from 1.5 to 2.0 was used for cDNA synthesis.
REVERSE TRANSCRIPTION
Generation of cDNA from RNA was done using iScript 
cDNA synthesis kit (Bio-Rad, USA) according to the 
manufacturer’s instructions. Briefly, a volume (containing 
1 μg) of total RNA from each sample was added to a mixture 
of 4 µL of 5X iScript reaction mix, 1 µL of iScript reverse 
transcriptase and a suitable volume of nuclease-free 
water (the final reaction mix volume is 20 μL). The final 
reaction mix was kept at 25°C for 5 min, 42°C for 30 min 
and heated to 85°C for 5 min in a thermocycler (TC-412, 
Techne, Barloworld Scientific, UK). The cDNA was then 
used as a template for amplification by polymerase chain 
reaction (PCR).
QUANTIFICATION OF GSTS GENE EXPRESSION BY 
QUANTITATIVE REAL-TIME PCR
Quantitative real-time PCR was performed on the 
MiniOpticon cycler (Bio-Rad, USA) to study the expression 
of GSTs gene namely glutathione S-transferase alpha 
1 (GSTA1), glutathione S-transferase alpha 3 (GSTA3), 
glutathione S-transferase mu 1 (GSTM1), glutathione 
S-transferase mu 3 (GSTM3) and glutathione S-transferase 
pi (GSTP). The total reaction volume used was 20 μL, 
consisting of 1 μL of 10 μM forward primer and 1 μL 
of 10 μM reverse primer (500 nM final concentration of 
each primer), 10 μL of iQ™ SYBR® Green Supermix (2X) 
(Bio-Rad, USA), 6 μL of nuclease-free water and 2 μL of 
cDNA. Both forward and reverse primers for the genes of 
interest in this study were designed according to previous 
studies (Kong et al. 2007; Xu et al. 2005) and synthesized 
by Vivantis Technologies (Oceanside, CA, USA). The primer 
sequences for the genes of interest are as shown in Table 1.
 The thermocycling conditions were initiated at 95°C 
for 30 s, followed by 40 PCR cycles of denaturation at 
95°C for 15 s and annealing/extension at 60°C for 30 s. 
At the end of each cycle, a melting curve (dissociation 
stage) analysis was performed in order to determine the 
specificity of the primers and the purity of the final PCR 
product. All measurements were performed in triplicate 
and no-template controls (NTC) were incorporated onto the 
same set of PCR tubes to test for contamination by any assay 
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reagents. Threshold cycles were determined for each gene 
and quantification of templates was performed according 
to the relative standard curve method. The relative gene 
expression (DDCt) technique, as defined in the Applied 
Biosystems User Bulletin No. 2 (Livak & Schmittgen 
2001), was used to analyse the real-time PCR data. In short, 
the expression level of each target gene was given as relative 
amount normalized against GAPDH standard controls.
TOTAL PROTEIN EXTRACTION FOR WESTERN BLOTTING
Liver tissue samples (0.1 g) were homogenized in 
0.5 mL RIPA lysis buffer (which contained 10 μL 
phenylmethylsulfonyl fluoride (PMSF), 10 μL sodium 
orthovanadate and 10 μL protease inhibitor cocktail solution 
per 1 mL of 1X RIPA lysis buffer). After centrifugation 
(13,000 × g for 30 min at 4°C), the supernatants were 
collected and their protein concentrations were determined 
using the Lowry method, with bovine serum albumin was 
used as standard (Lowry et al. 1951).
WESTERN BLOTTING
Standard Western blotting procedure was used for the 
immunodetection of proteins. Briefly, 100 μg of liver 
protein was separated using 15% sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) electrophoresis. The 
proteins in the gel were then transferred to a nitrocellulose 
membrane. The membrane was then incubated for 20 
min at room temperature in a blocking solution (150 mM 
NaCl, 3 mM KCl, 25 mM Tris, 0.1% (v/v) tween-20 and 
10% non-fat milk powder (pH7.4). After blocking, the 
membrane was incubated with the following antibodies: 
primary polyclonal rabbit anti-mouse GSTA, primary 
polyclonal rabbit anti-mouse GSTM1, primary polyclonal 
rabbit anti-mouse GSTP and primary polyclonal rabbit anti-
mouse actin for 1 h at room temperature. Subsequently, 
incubation with a peroxidase-conjugated goat anti-rabbit 
IgG secondary antibody was carried out for another hour 
at room temperature. Protein bands were visualized using 
the enhanced chemiluminescence method according to 
the manufacturer’s instructions (Amersham, Uppsala, 
Sweden). The intensity of the protein bands were 
quantified, relative to the signals obtained for actin, using 
ImageJ software.
STATISTICAL ANALYSIS
Data are presented as mean ± standard error of the mean 
(SEM). Significant differences between mean values of 
multiple groups were determined using one-way ANOVA 
and Student’s t-test. Statistical analysis was conducted 
using the SPSS software version 22. The result was 
considered statistically significant when p<0.05.
RESULTS
BODY WEIGHT AND FOOD INTAKE AFTER TRF TREATMENT
In order to investigate whether different doses of palm 
TRF affect body weight and food intake in the control and 
experimental mice, body weight of mice in each group were 
recorded and food intake of each mouse was individually 
measured every two days till the end of the treatment 
period. Table 2 shows that in palm TRF-treated groups, 
body weight and food consumption were only slightly 
inhibited by the administration of 1000 mg/kg TRF but 
they were not inhibited by the administration of 500 and 
200 mg/kg TRF. However, the difference in body weight 
and food consumption after 14 days was not statistically 
significant for all groups. Administration of BHA alone did 
not induce any significant alterations in those parameters 
and the results did not differ significantly from those of 
the control and TRF-treated groups.
LIVER GSTA1, GSTA3, GSTM1, GSTM3 AND                               
GSTP GENE EXPRESSION
To examine the effect of TRF administration on GSTs 
gene expression, mice were fed with different doses of 
TABLE 1. Primer sequence for GSTA1, GSTA3, GSTM1, GSTM3, GSTP and GAPDH
Gene Primer sequence Reference
GSTA1 F: 5’AGAATGGAGTGCATCAGGTGGTGGCTC 3’
R: 5’- GGCAGGCAAGTAACGGTTTTTGGT-3’
Xu et al. (2005)
GSTA3 F: 5’- GAGATCGACGGGATGAAACTGGTG-3’
R: 5’- GCGCTTTCAGGAGAGGGAAGTTGT-3’
Xu et al. (2005)
GSTM1 F: 5’- AGCACCCTGGCCTTCTGCACT-3’
R: 5’- TTCGCAGAAACGGGCTGTGAG-3’
Xu et al. (2005)
GSTM3 F: 5’- TGATTAGGCCCCTGCCATGCT-3’
R: 5’- TTGGGTCTGGGCACCAATGAA-3’
Xu et al. (2005)
GSTP F: 5’-TTTGGGGGCTTTATGGGAAAAACCA-3’
R: 5’-ACATAGGCAGAGAGCAGGGGGAAG- 3’
Xu et al. (2005)
GADPH F: 5’-GTGGAGTCTACTGGTGTCTTCA-3’
R: 5’-TTGCTGACAATCTTGAGTGAGT-3’
Kong et al. (2007) 
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TRF (200, 500, 1000 mg/kg) in the presence of vehicle-
treated control mice (fed corn oil) and a positive control 
group administered BHA (100 mg/kg) for 14 days. After 
14 days of treatment, the mice were sacrificed and the 
gene expression of various isoenzymes of GST in the liver 
was measured using quantitative real-time PCR (qPCR). 
As shown in Figure 1, TRF at concentrations of 200, 500, 
and 1000 mg/kg caused a significant dose-dependent 
increase in the fold change of GSTA1 gene expression 
levels (2.48 ± 0.39-fold (p<0.05), 3.13 ± 0.50-fold 
(p<0.05) and 4.40 ± 0.36-fold (p<0.001), respectively, 
as compared to controls). Mice treated with BHA (100 
mg/kg) showed the highest significant increase in GSTA1 
gene expression levels (7.46 ± 0.37-fold), compared to 
control mice (p<0.0001) and mice treated with 200, 500 
and 1000 mg/kg TRF (p<0.01).
 As shown in Figure 1, TRF at concentrations of 200, 
500 and 1000 mg/kg caused a significant dose-dependent 
increase in the fold change of GSTA3 gene expression 
levels (1.53 ± 0.03-fold (p<0.001), 2.71 ± 0.26-fold 
(p<0.01) and 3.93 ± 0.17-fold (p<0.0001), respectively, 
as compared to controls). Mice treated with BHA (100 
mg/kg) showed the highest significant increase in GSTA3 
gene expression levels (6.71 ± 0.22-fold), compared to 
control mice (p<0.0001) and mice treated with 200, 500 
and 1000 mg/kg TRF (p<0.001). 
 As shown in Figure 1, TRF at concentrations of 200, 
500 and 1000 mg/kg caused a significant dose-dependent 
increase in the fold change of GSTM1 gene expression 
levels (2.04 ± 0.12-fold (p<0.001), 2.40 ± 0.15-fold 
(p<0.001) and 3.23 ± 0.12-fold (p < 0.0001), respectively, 
as compared to controls). Mice treated with BHA (100 
mg/kg) showed the highest significant increase in GSTM1 
gene expression levels (7.33 ± 0.31-fold), compared to 
control mice (p<0.0001) and mice treated with 200, 500 
and 1000 mg/kg TRF (p<0.001).
 As shown in Figure 1, TRF at concentrations of 200, 
500 and 1000 mg/kg caused a significant dose-dependent 
increase in the fold change of GSTM3 gene expression 
levels (1.40 ± 0.03-fold (p < 0.05), 2.36 ± 0.12-fold (p < 
0.001) and 3.23 ± 0.09-fold (p < 0.0001), respectively, 
as compared to controls). Mice treated with BHA (100 
mg/kg) showed the highest significant increase in GSTM3 
gene expression levels (6.23 ± 0.23-fold), compared to 
TABLE 2. Body weight and food intake of control and treated mice
Groups  Body weight (bw) Food intake
 Day 1 (g) Day 14 (g) (g/bw/day)
Control
T200
T500
T1000
BHA
28.67 ± 2.13
27.67 ± 1.96
28.33 ± 1.25
31.67 ± 1.17
30.00 ± 1.32
33.33 ± 2.27
32.33 ± 2.11
30.33 ± 1.84
30.33 ± 2.18
30.67 ± 1.43
4.50 ± 1.11
4.37 ± 1.85
4.17 ± 1.92
2.09 ± 1.16
4.93 ± 1.23
T200, T500, T1000: Groups of mice treated with oral TRF at a daily dose of 200, 500 and 1000 mg/kg body weight, respectively. 
Control: control mice, BHA: positive control group that was given butylated hydroxyanisole (100 mg/kg). Values are given as mean 
± SEM (n = 6 for each group). No statistical significance was found between control and treated groups (ANOVA).
FIGURE 1. Effect of different doses of TRF on GSTA1, GSTA3, GSTM1, GSTM3 and GSTP gene expressions in the livers of 
mice. GAPDH served as the reference gene. Mice were treated with 200, 500 and 1000 mg/kg TRF for 14 days. Their livers 
were then harvested and the gene expression levels were determined using qPCR. Triplicate reactions were performed for 
each experiment and the values presented are the means of three independent experiments. Data is presented as mean ± 
SEM. T200: TRF at a dose of 200 mg/kg; T500: TRF at a dose of 500 mg/kg; T1000: TRF at a dose of 1000 mg/kg; C: control 
mice; BHA: positive control group given butylated hydroxyanisole (100 mg/kg). *Significant difference from control group 
(p<0.05). **Significant difference from control group (p<0.01). ***Significant difference from control group (p<0.001). 
****Significant difference from control group (p<0.0001). ##Significant difference from T1000, T500 and T200 groups 
(p<0.01). ###Significant difference from T1000, T500 and T200 groups (p<0.001)
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control mice (p < 0.0001) and mice treated with 200, 500 
and 1000 mg/kg TRF (p<0.001). 
 As shown in Figure 1, TRF at concentrations of 200, 
500 and 1000 mg/kg caused a significant dose-dependent 
increase in the fold change of GSTP gene expression levels 
(1.52 ± 0.04-fold (p<0.001), 2.03 ± 0.14-fold (p<0.01) and 
2.95 ± 0.28-fold (p<0.01), respectively, as compared to 
controls). Mice treated with BHA (100 mg/kg) showed the 
highest significant increase in GSTP gene expression levels 
(4.70 ± 0.14-fold), compared to control mice (p<0.0001) 
and mice treated with 200, 500 and 1000 mg/kg TRF 
(p<0.001).
LIVER GSTA, GSTM1 AND GSTP PROTEIN EXPRESSION
Administration of TRF at concentrations of 200, 500 and 
1000 mg/kg to mice for 14 days through oral gavage 
significantly increased liver GSTA protein (26 kd) expression 
levels by 1.80 ± 0.23-fold (p<0.05), 2.29 ± 0.16-fold 
(p<0.01) and 3.27 ± 0.17-fold (p<0.001), respectively, 
compared to controls. However, mice treated orally with 
BHA (100 mg/kg) for 14 days showed the highest significant 
increase in GSTA protein expression levels (7.58 ± 0.19-
fold), compared to control mice (p<0.00001) and mice 
treated with 200 (p<0.0001), 500 (p<0.0001) and 1000 mg/
kg TRF (p<0.001) (Figure 2).
 Administration of TRF at concentrations of 200, 
500 and 1000 mg/kg to mice for 14 days through oral 
gavage significantly increased liver GSTM1 protein (26 kd) 
expression levels by 2.78 ± 0.21-fold (p<0.01), 2.92 ± 0.26-
fold (p<0.01) and 3.85 ± 0.37-fold (p<0.01), respectively, 
compared to controls. Then, mice treated orally with BHA 
(100 mg/kg) for 14 days showed the highest significant 
increase in GSTM1 protein expression levels (5.01 ± 0.41-
fold), compared to control mice (p<0.01) and mice treated 
with 200, 500 and 1000 mg/kg TRF (p<0.05) (Figure 3).
 Administration of TRF at concentrations of 200, 500 
and 1000 mg/kg to mice for 14 days through oral gavage 
significantly increased liver GSTP protein (26 kd) expression 
levels by 1.56 ± 0.05-fold (p<0.001), 2.28 ± 0.14-fold 
(p<0.01) and 2.94 ± 0.17-fold (p<0.001), respectively, 
compared to controls. After 14 days, mice treated orally 
with BHA (100 mg/kg) for 14 days also showed the highest 
significant increase in GSTP protein expression levels (4.50 
± 0.19-fold), compared to control mice (p<0.001) and mice 
treated with 200 (p<0.001), 500 (p<0.01) and 1000 mg/kg 
TRF (p<0.01) (Figure 4).
 The observed effect of TRF on GSTA, GSTM1 and GSTP 
protein expression levels is in agreement with the observed 
effect on gene expression levels, in which both are enhanced 
in dose-dependent manner following administration of TRF. 
Meanwhile, the highest significant expression of GSTs gene 
and protein were observed when the mice were administered 
with BHA at the dose of 100 mg/kg, as indicated by the 
results of statistical analysis between the BHA and TRF 
groups presented in the figures and paragraphs.
DISCUSSION
The liver is the main organ responsible for the metabolism of 
most drugs and chemicals. Drug-metabolizing enzymes in 
*Significant difference from control group (p<0.05). **Significant difference from control group (p<0.01). ***Significant difference from control group 
(p<0.001). *****Significant difference from control group (p<0.00001). ###Significant difference from T1000 group (p<0.001). ++++Significant difference 
from T500 and T200 groups (p<0.0001)
FIGURE 2. Effect of different doses of TRF on GSTA liver protein expression. Mice were treated with 200, 500 and 1000 
mg/kg TRF for 14 days. Their livers were then harvested and GSTA protein expression levels were determined by Western 
blotting. The intensity of protein bands were quantified relative to the signals obtained for actin using ImageJ software, 
and was normalized to control. The graph represents the average optical density (± S.E.M.) of bands from three different 
experiments. T200: TRF at a dose of 200 mg/kg; T500: TRF at a dose of 500 mg/kg; T1000: TRF at a dose of 1000 mg/
kg; C: control mice; BHA: positive control group given butylated hydroxyanisole (100 mg/kg)
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the liver are involved in the metabolism, biotransformation 
and detoxification of drugs, toxic chemicals and their 
derivatives. Phase I enzymes i.e. the cytochrome P450s 
are found in the hepatocyte microsomes and catalyze 
various xenobiotic biotransformations (Almazroo et al. 
2017). Phase II enzymes such as the GSTs catalyze the 
detoxification of xenobiotics including carcinogenic 
chemicals. GSTs are involved in phase II metabolism and 
play important roles in protecting cells, organelles and 
macromolecules from various harmful entities (Hayes et 
al. 2005). GSTs stimulate nucleophilic attack via reduced 
glutathione (GSH) on nonpolar compounds containing an 
electrophilic carbon, making them less reactive and more 
hydrophilic (Cui et al. 2010; Knight et al. 2008). Tissues 
expressing high levels of GSTs (and other cytoprotective 
enzymes) are normally protected from damage by oxidants, 
harmful chemicals and xenobiotics (Bostwick et al. 
2007). Increasing the expression of these enzymes and 
their activities in vital organs such as the liver (which is 
subjected daily to oxidative stress and chemical insults) 
would definitely improve the liver detoxification potential.
The present study demonstrated the dose-dependent 
effects of TRF (200, 500 and 1000 mg/kg) on several GSTs 
(GSTA1, GSTA3, GSTM1, GSTM3 and GSTP) gene and protein 
expression levels, by means of qPCR and Western blot 
analysis, in the liver tissues of mice. The results obtained 
clearly showed that TRF positively induced the gene and 
protein expression levels of various GST isoenzymes in a 
dose-dependent manner, with the highest expression seen 
in mice treated with 1000 mg/kg. Our results also showed 
**Significant difference from control group (p<0.01). #Significant difference from T1000, T500 and T200 groups (p<0.05)
FIGURE 3. Effect of different doses of TRF on GSTM1 liver protein expression. Mice were treated with 200, 
500 and 1000 mg/kg TRF for 14 days. Their livers were then harvested and GSTM1 protein expression 
levels were determined by Western blotting. The intensity of protein bands were quantified relative to the 
signals obtained for actin using ImageJ software, and was normalized to control. The graph represents the 
average optical density (± S.E.M.) of bands from three different experiments. T200: TRF at a dose of 200 
mg/kg; T500: TRF at a dose of 500 mg/kg; T1000: TRF at a dose of 1000 mg/kg; C: control mice; BHA: 
positive control group given butylated hydroxyanisole (100 mg/kg)
**Significant difference from control group (p<0.01). ***Significant difference from control group (p<0.001). ##Significant difference from T1000 
and T500 groups (p<0.01). +++Significant difference from T200 group (p<0.001)
FIGURE 4. Effect of different doses of TRF on GSTP liver protein expression. Mice were treated with 200, 500 and 
1000 mg/kg TRF for 14 days. Their livers were then harvested and GSTP protein expression levels were determined 
by Western blotting. The intensity of protein bands were quantified relative to the signals obtained for actin using 
ImageJ software, and was normalized to control. The graph represents the average optical density (± S.E.M.) of 
bands from three different experiments. T200: TRF at a dose of 200 mg/kg; T500: TRF at a dose of 500 mg/kg; 
T1000: TRF at a dose of 1000 mg/kg; C: control mice; BHA: positive control group 
given butylated hydroxyanisole (100 mg/kg)
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that the liver GSTA gene expression showed the highest fold 
of increments amongst the GSTs (followed by GSTM and 
GSTP) after mice were administered with three different 
doses of TRF (200, 500 and 1000 mg/kg). However, the 
GSTM isoenzyme was the highest expressed at the protein 
level compared to other GSTs, after the administration of 
TRF to mice. Therefore it could be assumed that different 
isoenzymes of GST showed differential responses to TRF 
administration.
 Our findings showed that GSTA1, GSTA3, GSTM1, 
GSTM3 and GSTP expressions were significantly induced 
by all doses of TRF administered, with the highest level 
observed following TRF administration at a dose of 1000 
mg/kg, followed by 500 and 200 mg/kg, respectively. 
However, the highest observed level of GSTs expression 
induced by TRF was still below the expression levels 
induced by BHA treatment, as indicated by the statistical 
analysis performed. Since BHA is the classical inducer of 
phase II enzymes, it could be assumed that the increased 
antioxidant activities observed after tocotrienol treatment 
in previous animals studies might be partly mediated 
through the increased expression of phase II genes and 
proteins (Adam et al. 1996; Hsieh & Wu 2008; Lee et al. 
2009; Newaz & Nawal 1999).
 In our study, we used animal (mice) model and we 
looked specifically at the effect of TRF in the liver. Other 
studies which utilized in vitro techniques (mostly cell 
culture) have reported similar results. A previous in vitro 
study had investigated the effect of TRF on several cancer-
related gene expression using the estrogen-dependent 
(MCF-7) and estrogen-independent (MDA-MB-231) human 
breast cancer cell lines (Nesaretnam et al. 2004). They 
found that supplementation of TRF (8 µg/mL for 72 h) 
modulated significantly 46 out of 1200 genes in MDA-
MB-231 cells. In MCF-7 cells, TRF administration was 
associated with a lower number of affected genes. Out 
of all the genes affected, TRF administration significantly 
elevated the mRNA level of GST homologue in MDA-
MB-231 but not in MCF-7 cells (Nesaretnam et al. 2004). In 
Oxidative Stress-Induced Caenorhabditis elegans worms, 
TRF had been found to induce the expression of GSTP1 
protein (Aan et al. 2015). In another in vitro study involving 
human retinal pigment epithelial cells, pretreatment with 
α-tocopherol inhibited ROS generation, increased Nrf2 
expression and induced many phase II enzymes such as 
GST (Feng et al. 2010).
 In an in vivo study using rabbits, vitamin E 
supplementation induced up-regulation of GST expression 
in rabbit aortic tissues, which was correlated with elevated 
Nrf2 expression. These results suggested that vitamin 
E may afford protection against oxidative stress in 
atherogenesis via an Nrf2 redox-regulated pathway in the 
rabbit aorta (Bozaykut et al. 2014). Additionally, treatment 
with 0.1% γ-tocopherol-enriched mixed tocopherol 
diet (γ-TmT) for a period of 24 weeks upregulated the 
expression of GSTM1 gene and protein levels and inhibited 
tumour development in the prostate of the murine prostate 
cancer model (TRAMP) mice (Barve et al. 2009).
 In our study, TRF was able to increases hepatic GSTs 
levels in wild type mice. The antioxidant activities of 
tocotrienols (which are the major components of TRF) 
have been linked to Nrf2 activation in an in vitro study 
(Hsieh et al. 2010). However, the exact mechanism by 
which tocotrienol/TRF induce GSTs protein expression 
in mice liver is still not fully understood. Since GSTs are 
phase II enzymes and phase II enzymes are regulated by 
Nrf2 (Aleksunes & Manautou 2007), it is suggested that 
tocotrienols (either directly or indirectly through their by-
products) are able to dissociate the Nrf2/Keap1 complex, 
allowing Nrf2 to translocate to the nucleus and increase 
the expression of phase II enzymes (including the GSTs) in 
the liver cells. Further studies are needed to confirm this 
mechanism.
 The activity of GSTs enzymes was significantly increased 
during diethylnitrosamine (DEN)/2-acetylaminofluorene 
(AAF)-induced hepatocarcinogenesis in rats. However, TRF 
treatment to DEN/AAF-treated rats substantially decreased 
the activity of GSTs enzymes (Iqbal et al. 2004; Makpol 
et al. 1997). Similarly, TRF maintained low levels of GST 
activities in liver and mammary glands of DMBA-treated 
rats (Iqbal et al. 2003). In these cases, it is postulated that 
increased GSTs activities was able to prevent further organ/
tissue damage caused by those carcinogens. Administration 
of TRF was thought to attenuate lipid peroxidation due to its 
free radical scavenging properties and halted the process 
of organ/tissue damage and therefore less GSTs enzyme 
activities was needed to counter the redox imbalance in 
those organs/tissues, thus leading to substantially decreased 
GSTs activity. However, the gene and protein expression of 
GSTs was not measured in those studies and their expression 
might still be up-regulated even though their activities had 
decreased (feedback mechanism).
 On the other hand, pretreatment of LPS, turpentine 
or zymosan-stressed hamsters with tocotrienol enriched 
diet resulted in a significant increase of GST activities 
in the liver and kidney (Khan et al. 2011). In another 
study, supplementation of vitamin E restored the activity 
of GST in the kidneys of tenofovir-treated Wistar albino 
rats (Adaramoye et al. 2012). However, in light of the 
knowledge that tocotrienols are the major chain-breaking 
antioxidants, it might be suggested that tocotrienols are 
able to counter the oxidative stress condition caused by the 
damage to biological membranes by free radicals, resulting 
in the production of protein carbonyl adducts. It is thought 
that these protein carbonyl adducts (or other by-products 
produced during tocotrienol-related counter-attack on free 
radicals) are able to dissociate the Nrf2/Keap1 complex, 
allowing Nrf2 to translocate to the nucleus and eventually 
activates a diverse cytoprotective genes (Bruno & Traber 
2006; Gao et al. 2007). However, extensive biochemical 
assays are needed to confirm such interaction.
CONCLUSION
As discussed, increased expression of GSTs in the liver 
could potentially protect the liver from oxidative and 
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chemicals insults. Excessive oxidative and chemical 
insults to the liver could potentially cause acute/chronic 
liver damage and carcinogenesis. In order to prevent 
such ailments to occur, it would be wise to take some 
chemopreventive measure. In this respect, increasing the 
expression of various isoforms of GSTs by pharmacological 
means, offers a potential new therapeutic target for liver 
degenerative diseases. In our study, TRF had been shown 
to be able to increase the expression of various isoenzymes 
of GST in a dose-dependent manner. Therefore, the 
recommended therapeutic dose of TRF which is effective 
in the prevention or treatment of liver diseases in humans 
should be aggressively investigated. Consuming palm oil 
TRF in the form of supplements could be an affordable 
chemoprotective measure in the long run. Further studies 
are needed to conclusively support this strategy.
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